Format

Send to

Choose Destination
Br J Cancer. 2017 Jan 17;116(2):265-269. doi: 10.1038/bjc.2016.400. Epub 2016 Dec 13.

Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.

Author information

1
Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine and UNM Comprehensive Cancer Center, University of New Mexico, MSC 10 5550, 1 UNM, Albuquerque, NM 87131, USA.
2
University of Calgary, Department of Community Health Sciences, Alberta Health Services, Calgary, Alberta, Canada.
3
UNM Comprehensive Cancer Center, University of New Mexico, MSC 07-4025, 1 UNM, Albuquerque, NM 87131, USA.
4
Cancer Control Research, BC Cancer Research Centre, 675W. 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.
5
Obstetrics and Gynecology, University of Alberta, 10240 Kingsway Avenue, Edmonton, Alberta T5H 3V9, Canada.
6
Department of Oncology and Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary, 1331 29th Street NW, Calgary, Alberta T2N 4N2, Canada.
7
Medical Oncology, BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
8
Department of Anatomic Pathology, H Lee Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.
9
Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, 2AA-07, 3280 Hospital Dr NW, Calgary, Alberta T2N 2Z6, Canada.
10
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Ave, Vancouver, British Columbia V5Z 1L3, Canada.
11
Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.

Abstract

BACKGROUND:

Combined oral contraceptive (COC) use reduces epithelial ovarian cancer (EOC) risk. However, little is known about risk with COC use before the first full-term pregnancy (FFTP).

METHODS:

This Canadian population-based case-control study (2001-2012) included 854 invasive cases/2139 controls aged ⩾40 years who were parous and had information on COC use. We estimated odds ratios (aORs) and 95% confidence intervals (CI) adjusted for study site, age, parity, breastfeeding, age at FFTP, familial breast/ovarian cancer, tubal ligation, and body mass.

RESULTS:

Among parous women, per year of COC use exclusively before the FFTP was associated with a 9% risk reduction (95% CI=0.86-0.96). Results were similar for high-grade serous and endometrioid/clear cell EOC. In contrast, per year of use exclusively after the FFTP was not associated with risk (aOR=0.98, 95% CI=0.95-1.02).

CONCLUSIONS:

Combined oral contraceptive use before the FFTP may provide a risk reduction that remains for many years, informing possible prevention strategies.

PMID:
27959890
PMCID:
PMC5243988
DOI:
10.1038/bjc.2016.400
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center